Relay Therapeutics, Inc. RLAY Proceeds From Issuance Of Common Stock Through Exercise Of Stock Options

Proceeds From Issuance Of Common Stock Through Exercise Of Stock Options at other companies

NuScale PowerSMR

$1.6M-71.4%

GlobalstarGSAT

$1.33M+96.7%

Duos Technologies Group, Inc.DUOT

$16.03K-85.2%

Butterfly NetworkBFLY

$2.72M+1,830%

City Holding CompanyCHCO

$0-100%

McEwen MiningMUX

$14.83M+1,119%

FAQ

What is Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options?

Relay Therapeutics, Inc. (RLAY) reported proceeds from issuance of common stock through exercise of stock options of $131K in Q4 2025.

How has Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options changed year-over-year?

Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options decreased by 81.2% year-over-year, from $695.5K to $131K.

What is the long-term trend for Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options?

Over 3 years (2022 to 2025), Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options has grown at a -46.8% compound annual growth rate (CAGR), from $3.48M to $524K.

What does proceeds from issuance of common stock through exercise of stock options mean?

Captures the cash received from employees or directors exercising vested stock options granted as part of compensation packages. This metric reflects the conversion of equity-based incentives into actual share ownership and provides a modest source of cash inflow. It is often viewed as a signal of internal alignment between employee compensation and shareholder value.